IL22 and colitis: Altogether, the JAKinib tofacitinib, when provided not too early, is very efficient in limiting clinical signs of DSS-induced colitis and the expression of pro-inflammatory cytokines, while supporting Treg cells, IL-10 and IL-22 expression.